Cardiac amyloidosis: New insights into diagnosis and management

Reviews in Cardiovascular Medicine

Volumn 8, Issue 4, 2007, Pages 189-199

  Eshaghian, Shervin ^a   Kaul, Sanjay ^a   Shah, Prediman K ^a  

^a NONE

Author keywords

Amyloidosis; Congestive heart failure; Diuretics; Dyspnea; Hypotension

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPRODISATE; FIBRINOGEN; GELSOLIN; GENISTEIN; ISOLEUCINE; LYSOZYME; MELPHALAN; PREALBUMIN; PREDNISONE; TROPONIN; UNCLASSIFIED DRUG;

AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CACHEXIA; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIAGNOSTIC IMAGING; DIASTOLIC DYSFUNCTION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; FAMILIAL AMYLOIDOSIS; HEART AMYLOIDOSIS; HEART ATRIUM ENLARGEMENT; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE COMPLIANCE; HEART MUSCLE RELAXATION; HEART SCINTISCANNING; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POINT MUTATION; PREVALENCE; PROGNOSIS; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SEX DIFFERENCE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

AMYLOIDOSIS; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; CARDIOMYOPATHY, RESTRICTIVE; CARDIOVASCULAR AGENTS; DRUGS, INVESTIGATIONAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART CATHETERIZATION; HEART DISEASES; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 38349019898     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2002. Amyloid. 2002;9:197-200.
2. Vircho VR. Ueber einem Gehirn and rueckenmark des Menschen auf gefundene Substanz mit chemischen reaction der Cellulose. Virchows Arch Pathol Anat. 1854;6:135-138.
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596.
4. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909.
5. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmstead County, Minnesota, 1950 through 1989. Blood. 1992;79:1817-1822.
6. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141-157.
7. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
8. L germ line gene use and clonal plasma cell burden. Blood. 2001;98:714-720.
9. Merlini G, Westermark P. The systemic amyloidosis: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004;255:159-178.
10. Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidosis: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A. 2004;101:2817-2822.
11. Jacobson DR, Buxbaum JN. Genetic aspects of amyloidosis. Adv Hum Genet. 1991;20:69-123.
12. Jacobson DR, Pastore R, Pool S, et al. Revised transthyretin Ile122 allele frequency in African-Americans. Hum Genet. 1996;98:236-238.
13. Jacobson DR, Pastore DR, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336:466-473.
14. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated (AL) amyloidosis. Arch Intern Med. 2005;165:1425-1429.
15. Wright JR, Calkins E. Amyloid in the aged heart: frequency and clinical significance. J Am Geriatr Soc. 1975;23:97-103.
16. Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24-29.
17. Gal R, Korzets A, Schwartz A, et al. Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis: report of seven cases and review of the literature. Arch Pathol Lab Med. 1994;118:718-721.
18. Miller WL, Wright RS, McGregor CG, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol. 2001;88:813-815.
19. Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol. 1998;31:754-765.
20. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440-2445.
21. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787-1789.
22. Siqueira-Filho AG, Cunha CL, Tajik AJ, et al. M-mode and two dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981;63:188-196.
23. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6:737-743.
24. Falk RH, Plehn JF, Deering T, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol. 1987;59:418-422.
25. Klein AL, Hatle LK, Burstow DJ, et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1989;13:1017-1026.
26. Klein AL, Hatle LK, Taliercio CP, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990;16:1135-1141.
27. Koyama J, Ray-Sequin PA, Davidoff R, Falk RH. Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol. 2002;89:1067-1071.
28. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr. 2004;17:36-44.
29. Swanton RH, Brooksby IA, Davies MJ, et al. Systolic and diastolic ventricular function in cardiac amyloidosis: studies in six cases diagnosed with endomyocardial biopsy. Am J Cardiol. 1977;39:658-664.
30. Falk RH, Lee VW, Rubinow A, et al. Sensitivity of technetium-99m- pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983;51:826-830.
31. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2- propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076-1084.
32. Hazenberg BP, Van Rijswijk MH, Piers AD, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006;119:e15-e24.
33. Fattori R, Rocchi G, Celletti F, et al. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J. 1998;136:824-830.
34. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-193.
35. Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:122-124.
36. Libbey CA, Skinner M, Cohen AS. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med. 1983;143:1549-1552.
37. Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration. Am J Med. 1987;82:412-414.
38. Kyle RA, Spencer RJ, Dahlin DC. Value of rectal biopsy in the diagnosis of primary systemic amyloidosis. Am J Med Sci. 1966;251:501-506.
39. Abraham RS, Katzmann JA, Clark RJ, et al. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol. 2003;119:274-278.
40. Gertz MA, Falk RH, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985;55:1645.
41. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest. 1993;104:618-620.
42. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63:1285-1288.
43. Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J. 1995;74:541-544.
44. Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol. 1997;80:1491-1492.
45. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
46. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicines only. Am J Med. 1996;100:290-298.
47. Gertz MA, Blood E, Vesole DH, et al. Amyloidosis: a multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Manow Transplant. 2004;34:149-154.
48. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766-769.
49. Hosenpud JD, Uretsky BF, Griffith BP, et al. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey. J Heart Transplant. 1990;9:346-350.
50. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23:1142-1153.
51. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation: follow-up results of a multicenter survey. Circulation. 1991;84(5 suppl):III338-III343.
52. Heart transplantation: effective treatment for selected patients with amyloidosis. Mayo Clinic Cardiovascular Update. 2007;5:3-4.
53. Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transplant. 2000;6:263-276.
54. Ruygrok PN, Gane EJ, McCall JL, et al. Combined heart and liver transplantation for familial amyloidosis. Intern Med J. 2001;31:66-67.
55. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005;118:552-556.
56. Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial Mediterranean fever. A double-blind trial. N Engl J Med. 1974;291:934-937.
57. Kelly JW. Attacking amyloid. N Engl J Med. 2005;352:722-723.
58. Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci U S A. 2005;102:14545-14550.
59. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002;417:254-259.
60. Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med. 1995;1:143-148.
61. Dember LM, Hawkins PN, Hazenberg BP, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356:2349-2360.